IMI- Innovative Medicines Initiative Joint Undertaking

IMI- Innovative Medicines Initiative Joint Undertaking is a unique pan-European public private partnership aiming to foster collaboration between all relevant stakeholders including large and small biopharmaceutical and healthcare companies, regulators, academia and patients.

Call Scientific Priorities:
 Assessment of drug induced toxicity in relevant organs - surrogates for early drug failure
 Immunological Safety of Biopharmaceuticals
 Assessment inflammatory disease
 Improve the scientific and pre-clinical infrastructure for Tuberculosis medicine
 Enhancing translation in neurological disease
 Development of personalized medicine approaches in diabetes
 Fostering a broader understanding of pharmaceutical R&D in the broader public

Further Information:
http://www.imi.europa.eu/content/stage-1 

Contact Person:
David Shem-Tov - david.s@tx.technion.ac.il
Jacky Lavan - jackl@dp.technion.ac.il